Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast Cancer
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
To provide an in vivo measure of the activity of lapatinib. To assess the antiproliferative
effects of lapatinib in breast cancer, ie how much lapatinib slows down the growth of cancer
cells by measuring K167 (a marker of proliferation) in breast tumours before and after a
short treatment with lapatinib.